|
|
|
In the April issue of Nature Medicine, Vicente Torres and colleagues report a new treatment for polycystic kidney disease (PKD), the fourth leading cause of kidney failure in the US.
PKD is a genetic disorder in which kidneys become overgrown with fluid-filled cysts. The authors tested the drug OPC31260, which blocks an important receptor in kidney cells, in a mouse model of autosomal dominant PKD, the most common form of the disease. The drug blocked disease development in the mice, reducing the number of kidney cysts and preventing the kidneys from becoming enlarged. The authors say OPC31260 and similar drugs should be safe in clinical studies because they specifically target the kidneys. Other drugs targeting the same receptor are currently in clinical trials for diseases such as congestive heart failure and cirrhosis. Author contact: Vicente E. Torres
Mayo Clinic
Rochester, MN
USA
Tel: +1 507 284 2908
E-mail: torres.vicente@mayo.edu Also available online. (C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|